is expanding its CRO activities through the acquisition of Prudentas
. ChemDiv believes that Prudentas’ range of services covering Phase I through Phase IV studies in Eastern Europe will add to its Discovery outSource™.
“Our decision to make this investment capitalizes on the growing trend of conducting clinical trials in Eastern Europe based on the availability of naive patient populations, rapid and efficient trial recruitment, and high data quality across a broad range of therapeutic indications including CNS, cardiovascular and metabolic disorders, oncology, inflammation, and infectious disease; areas already covered by our Discovery outSource service,” explains Nikolay Savchuk, president and CEO of ChemDiv.
ChemDiv previously worked with Prudentas in response to a growing partner base interested in conducting clinical trials. Now ChemDiv’s ChemRar High Tech Center will take over Prudentas. It will operate separately under the business name Prudentas LLC, a ChemDiv Group company.